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Plasma oxytocin (OT) and arginine vasopressin (AVP) are associated with individual
differences in emotional responses and behaviors. The amygdala is considered to be
an important brain region for regulating emotion-based behavior, with OT and AVP
modulating activity in the amygdala during the processing of negative emotions. In
particular, increased OT levels may diminish amygdala activation (anxiolytic effects)
and enhanced AVP levels may augment amygdala activation (anxiogenic effects) when
negative emotions are processed. A growing body of research has shown that the effects
of OT and AVP are modulated by sex: the aforementioned anxiolytic effects of OT and
the anxiogenic effects of AVP occur in men, but not in women. However, we have little
knowledge regarding the biological mechanisms underlying OT and AVP plasma levels
or their respective anxiogenic and anxiolytic effects; similarly, little is known about the
causes and nature of sex differences related to these neuropeptides and their effects on
emotional processing. In the current study, we focused on the neural functions associated
with the biological mechanisms underlying such effects. We hypothesized that amygdala
activation would correlate with trait plasma OT (anxiolytic effects) and AVP (anxiogenic
effects) levels because the amygdala is thought to affect the coordinated release of
these neuropeptides following affective experiences. We further hypothesized that the
effects would be modulated by sex. We assessed 51 participants (male and female)
using a paradigm involving negative emotion in conjunction with functional magnetic
resonance imaging and measurements of plasma OT and AVP levels. We determined
that increased plasma AVP levels were positively associated with amygdala activation
(anxiogenic effects) in men, but not in women. These findings highlight the potential
underlying neural mechanisms of plasma AVP levels in men.
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INTRODUCTION
Emotions are basic human biological features; to survive in
everyday life requires the ability to monitor, evaluate, and modify
our emotional states, and to adaptively express our emotions.
However, not all humans process their emotional experiences
in the same manner, with individual differences arising in the
evaluation and expression of emotions upon encountering affect-
inducing experiences. These individual differences are known to
depend on personality traits, cognitive factors, and situational
influences (Buchanan et al., 1999; Kim et al., 2004; Drabant
et al., 2009; Somerville et al., 2013). In addition, neuropeptides
(e.g., as manifested in their central and plasma concentrations)
modulate individual responses to affective stimuli (Holmes et al.,
2003). Despite the known importance of neuropeptides with
respect to emotional responses, the mechanisms that govern
individual differences and the means by which they modulate
neural responses to emotional experiences have not been fully
elucidated.
Among the various neuropeptides, the affective functions of
oxytocin (OT) and arginine vasopressin (AVP) in particular
have increasingly drawn the attention of researchers (Caldwell
et al., 2008; Raggenbass, 2008; Meyer-Lindenberg et al., 2011).
While OT is involved in sexual reproduction, and AVP affects
water retention and vasoconstriction, individual differences
in plasma OT and AVP are also implicated in emotional
behaviors and affective disorders, though there is considerable
controversy regarding the relationship between peripheral levels
of these neuropeptides and their central availability (Meyer-
Lindenberg et al., 2011). For example, their concentrations in
cerebrospinal fluid (CSF), a global measure of the central release
of neuropeptides, are positively correlated with plasma levels in
some studies (Bartrons et al., 1992), but not in others (Wu and
Keysar, 2007).
Although there is still controversy regarding the relationship
between peripheral levels of these neuropeptides and their central
availability, numerous studies have used plasma OT and AVP
shows the associations between emotional variables and plasma
OT and AVP, which implies that their plasma levels reflect
their central levels. For example, lower plasma OT levels and
higher AVP levels have been linked with several psychiatric
disorders, including major depressive disorders (Londen et al.,
1997; de Winter et al., 2003) and posttraumatic stress disorder
(De Kloet et al., 2008), that have been characterized as involving
increased amygdala activation (Siegle et al., 2002; Etkin and
Wager, 2007). Hence, the augmented activation of the amygdala
during emotional processing that is present in these psychiatric
disorders may be due to decreased OT and increased AVP
levels. The above findings led us to view OT as potentially
exerting anxiolytic effects (i.e., decreased amygdala activation for
negative emotions) and AVP as inducing anxiogenic effects (i.e.,
augmented amygdala activation for negative emotion).
It is known that sex modulates the anxiolytic effects of OT
and the anxiogenic effects of AVP. Evidence has accumulated
indicating that AVP exerts anxiogenic effects in men but not
in women. For example, higher AVP levels, which may be
linked with augmented amygdala activation during emotional
processing, have been associated with an increase in traits related
to negative affect in men, but not in women (Taylor et al., 2010).
Furthermore, AVP administration has been shown to increase
amygdala activation in male subjects perceiving fearful stimuli
(Brunnlieb et al., 2013; Lee et al., 2013). In contrast, the anxiolytic
effects of OT are more complex and may exert an opposite
sex-based difference. Notably, intranasally administered OT was
found to decrease amygdala activation in men (Kirsch et al.,
2005; Domes et al., 2007; Petrovic et al., 2008; Labuschagne
et al., 2010; Riem et al., 2011), but increase it in women
(Domes et al., 2007; Lischke et al., 2012). In addition, plasma
OT is negatively correlated with trait anxiety, which is related
to increased amygdala activation during emotional processing
(Stein et al., 2007) in men but not in women (Weisman et al.,
2013). These findings suggest that the anxiogenic effects of AVP
and the anxiolytic effects of OT appear in men but not in women.
As indicated in the above discussion, numerous studies have
used plasma OT and AVP as a measure of individual differences
pertinent to the anxiolytic effects of OT and the anxiogenic effects
of AVP, assuming that their plasma levels reflect their central
levels. However, the underlying biological mechanisms of the
anxiogenic effects of AVP and the anxiolytic effects of OT remain
unclear Accordingly, the present study aimed to investigate
the biological mechanisms underlying the relationships between
plasma levels of OT and AVP and their anxiogenic and anxiolytic
effects, and how sex differences may modulate these effects.
We hypothesized that the amygdala would be a key region
for investigating the underlying biological functions of individual
differences pertaining to the anxiolytic effects of OT and the
anxiogenic effects of AVP, with anxiolytic effects manifesting
as decreased amygdala activation correlated with OT, and
anxiogenic effects as increased amygdala activation correlated
with AVP during the processing of negative emotion. First, the
anxiolytic effects of OT and the anxiogenic effects of AVPmay be
mediated by receptors in the amygdala (Meyer-Lindenberg et al.,
2011). Although receptors for OT and AVP are widely expressed
in the hypothalamus and the bed nucleus of the stria terminalis as
well as in the amygdala (Loup et al., 1991; Veinante and Freund-
Mercier, 1997; Young et al., 1999), among these, the amygdala
is critically involved in the processing of negative emotions
(Öhman, 2005). Injections of OT or AVP in the amygdala were
found to decrease or increase, respectively, fearful behaviors
related to depressive symptoms in animals (Huber et al., 2005;
Salome et al., 2006). All of this evidence suggests that activity in
the amygdala is related to plasma levels of OT and AVP during
aversive experiences. Second, the amygdala may be a potential
target for communication between central and peripheral OT
and AVP release following negative affective responses, and as
a result, baseline levels of OT and AVP may partially reflect
their central levels in the amygdala; however, the details of the
potential mechanisms remain unclear (McCullough et al., 2013).
An experimental model of peripheral and central communication
with respect to these neuropeptides suggests that following a
response to an affective stimulus, OT and AVP are released in
the amygdala because this region contains high densities of OT
and AVP neurons and receptors. Subsequently, affective OT-
and AVP-derived responses in the amygdala are transmitted to
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other limbic regions, leading to the projection of magnocellular
hypothalamic OT and AVP neurons to the posterior pituitary.
Finally, these neuropeptides are conveyed to peripheral routes
through the posterior pituitary (Neumann and Landgraf,
2012). However, there is no evidence to determine whether
amygdala activation during the processing of negative emotion
is associated with individual differences in OT and AVP plasma
levels.
This study aimed to investigate the biological mechanisms
underlying the anxiolytic effects of OT and the anxiogenic effects
of AVP related to the peripheral levels of these neuropeptides
and to identify any sex-based modulation. To this end, we
investigated the potential association between plasma OT and
AVP levels and amygdala activation during the processing of
negative emotions in both men and women. To conduct our
investigation, we used functional magnetic resonance imaging
(fMRI) and a negative emotion paradigm known to robustly
induce amygdala activation (Ochsner et al., 2009; Silvers et al.,
2015). We hypothesized that: (1) decreased amygdala activation
during the processing of negative emotion (anxiolytic effects)
would be associated with elevated plasma OT levels in men
but not in women; and (2) that increased amygdala activation
during negative emotional responses (anxiogenic effects) would
be associated with elevated plasma AVP levels in men but not in
women.
METHODS
Participants
A total of 73 healthy, right-handed volunteers with no history
of neurological or psychiatric illness participated in our fMRI
study. Participants were recruited through notices on the
university campus and announcements in local newspapers.
They provided written informed consent after receiving an
explanation regarding the nature of the experiment. This study
was performed concomitantly with another intervention study
investigating the effects of training on shadowing, compressed
speech, and reading aloud. These studies shared a pool of
active control group subjects, psychological and neuroimaging
outcomemeasures, a training period, training times, and training
frequencies. All procedures were conducted according to the
Declaration of Helsinki. The experimental protocol was approved
by the ethics committee of the Tohoku University School of
Medicine.
We removed participants who did not perform the fMRI
task or who exhibited excessive bodily movements during MRI
(n = 4), as well as those whose plasma level of either
OT or AVP was below the detection threshold or missing
a value (n = 17). We then converted plasma OT and
AVP to log values, and subjects with OT or AVP values
that exceeded three standard deviations (SD) were removed
(n = 1). We ultimately used data from a total of 51 subjects
(age: 18–26 years; 27 males). The mean age was in 20.63 ±
1.690 for men, and 20.17 ± 0.917 for women. The mean
OT value was 20.9392 pg/mL ± 5.93579 for all participants,
21.7667 pg/mL± 7.25253 for men, and 20.0083 pg/mL±3.92771
for women. The mean AVP value was 1.874510 pg/mL ±
1.1014251 for all participants, 2.1148 pg/mL± 1.29011 for men,
and 1.6042 pg/mL ± 0.78213 for women. Data pertaining to
the women’s menstrual cycles on the day of blood sampling
was available for 23 of the 24 women (menstrual phase:
n = 5; luteal phase: n = 6; follicular phase: n = 12).
These menstrual cycle stages were categorically coded for
further analysis (menstrual phase = 0; luteal phase= 1;
follicular phase = 2). None of the women were taking oral
contraceptives.
Assessment of Chronic Negative Affect
Trait anxiety levels were assessed using the Japanese version
of the State-Trait Anxiety Inventory (STAI) (Spielberger, 2010).
Data were available for 49 of the 51 participants.
Laboratory Trait Plasma OT and AVP
Biomarkers
To capture baseline (i.e., trait) levels of plasma OT and
AVP, we obtained heparinized blood samples on a single day
from the antecubital vein of subjects after they had rested
for 15min. Sampling occurred within 1 week of the MRI
experiment and blood was obtained between 2:00 and 5:00
p.m. to minimize diurnal variation among subjects. The blood
samples were centrifuged at 2000 × g at 4◦C for 25min,
and the plasma was subsequently harvested and frozen at
−80◦C until further investigation. We assessed plasma OT levels
using a commercially available enzyme immunoassay kit with
a detection limit of (Enzo Life Sciences, Inc., Farmingdale, NY,
USA). Validation of this assay procedure has been described
(Sue Carter et al., 2007) and repeatedly conducted in previous
studies investigating plasma OT in humans (Feldman et al.,
2007, 2010). All sample extraction and concentration procedures
were conducted at the LSI Medicine Corporation (Sendai,
Japan) in accordance with the official kit manual. Although
OT levels fluctuate between the time of blood sampling and
brain scanning (especially in females), our assay indicated a
reliable stability from day-to-day. According to the assay’s
protocol, the inter-assay coefficients of variability are lower than
20.9% and the intra-assay coefficients are lower than 13.3%
(Enzo Life Sciences, Inc.). The assay also refers to the stability
of inter- and intra-assay coefficients of variability observed
in a previous study (Lancaster et al., 2015). A natural log
transformation was applied to correct any skewing in plasma OT
values.
Plasma AVP levels were similarly measured according to the
manufacturer’s instructions, using an AVP radioimmunoassay
(RIA) Neo double antibody method (LSI Medicine Corporation)
with a detection limit of 0.8 pg/mL. This assay was used in a
prior study (Imamura et al., 2014). Although AVP levels fluctuate
between during the time of blood sampling and brain scanning
(especially in females), our assay indicated the reliable stability
from day-to-day. According to the manufacturer’s protocol,
the inter- and intra-assay coefficients of variability are less
than 10%, indicating remarkable stability of the samples and
reliability of the assay (LSI Medicine Corporation). A natural log
transformation was applied to correct skewing of the plasma AVP
values.
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fMRI Stimuli
A total of 26 negative and 13 neutral pictures, according to
normative ratings, were selected from the International Affective
Picture System (IAPS). On a 9-point scale, the mean valence and
arousal values for the neutral pictures were 5.149 ± 0.191 and
3.401 ± 0.459, respectively, and for the negative pictures, 2.067
± 0.387 and 6.157± 0.606, respectively (1: most unpleasant/least
arousing; 9: most pleasant/most arousing) (Lang et al., 1997).
Emotional Reactivity Task
The emotional reactivity task was conducted as described in
previous studies (Ochsner et al., 2009; Wager et al., 2013). This
task consists of three conditions, Look Neutral (viewing of a
neutral picture), Look Negative (viewing of a negative picture),
and Decrease Negative (reinterpretation of a negative picture),
and permits contrasts related to blood oxygen level-dependent
(BOLD) signal changes evoked by naturally occurring emotional
reactions to negative stimuli (Look Negative vs. Look Neutral).
We focused on the Look Neutral and Look Negative conditions
for our objective evaluation of emotional reactivity. The Decrease
Negative condition was used in our other study, which ran
concomitantly with the current one; its purpose was unrelated
to the present research. For the Look Neutral and Look Negative
conditions, participants were shown either neutral or aversive
images and were instructed to react naturally to the stimuli (i.e.,
without reappraising them). In contrast, in the Decrease Negative
condition, subjects were instructed to reappraise the images in a
way that reduced their negative impact.
Each trial proceeded as follows. First, an instruction (“Look”
or “Decrease”) appeared on the screen for 2 s (as indicated above,
the results following the instruction to “Decrease” will be detailed
elsewhere because this instruction aimed to investigate emotional
regulation, which is outside the scope of the present study).
Subsequently, a neutral or negative image was presented for
7 s. A fixation cross then appeared for a variable interstimulus
interval (1–3 s), followed by an emotional rating phase of 2 s in
duration. During the rating phase, participants were asked to rate
the strength of their negative feelings on a scale of 1–8 (1 = not
negative at all, 8 = very negative), which appeared from left to
right on the screen. The directionality of the affective rating scale
was counter-balanced so that half the trials used a reversed scale
with 8 on the left and 1 on the right side of the screen; this was
done to prevent hand movement preparation during exposure
to the emotional picture. After the emotional rating phase, the
trial concluded with a fixation cross that appeared for a variable
duration of 1–3 s.
Thirteen negative images were preceded by the “Look”
instruction, and 13 negative images were preceded by the
“Decrease” instruction. An additional 13 neutral images were
preceded by only the “Look” instruction because no emotional
regulation is required for neutral images. The three conditions
(Look Neutral, Look Negative, and Decrease Negative) were
randomly intermixed throughout the experiment to avoid
habituation to the same type of instructions or images appearing
consecutively. Prior to scanning, participants received an
explanation of reappraisal and reactivity strategies. During this
time, participants were also reminded not to look away from
the images or distract themselves with irrelevant and/or positive
thoughts unrelated to the images. After all of the instructions
had been conveyed, participants received a brief training session
regarding emotional reactivity and regulation. The images
used during training were different from those used during the
subsequent test.
Behavioral Analyses
To determine the relationships between plasma OT and AVP
levels and subjective reports of negative emotions during the
emotional reactivity task, we performed multiple regression
analyses using SPSS (version 21; IBM, Armonk, NY, USA). We
used subjective scores of negative emotion as predictors. First,
using OT (or AVP), age, and sex as explanatory variables, we
analyzed the relationship between OT (or AVP) and negative
emotion scores. Second, using the OT-by-sex (or AVP-by-sex)
interaction term, OT (or AVP), age, and sex (coded as men
= 1, women = −1) as explanatory variables, we analyzed the
relationship between OT-by-sex (or AVP-by-sex) and negative
emotion scores. OT, AVP, sex, and their interaction terms were
centered in the second analysis to avoid multicollinearity. Also,
menstrual cycle stages were categorically coded and entered
into multiple regression analyses for no-interests of explanatory
variables (menstrual phase= 0; luteal phase= 1; follicular phase
= 2).The analyses were performed using SPSS (version 22). All
tests were two-tailed, with a threshold of p < 0.05.
fMRI Methods and Data Acquisition
For all sessions, 42 transaxial gradient-echo images (echo
time= 10ms, flip angle = 90◦, slice thickness = 3mm, slice gap
= 0mm, field of view [FOV]= 192mm, matrix= 64× 64, voxel
size= 3×3× 3mm) covering the entire cerebrumwere acquired
at a repetition time of 2.5 s using an echo planar sequence and an
Achieva (3T) MR scanner (Philips, Amsterdam, Netherlands).
The following preprocessing procedures and subsequent
statistical analyses were performed using Statistical Parametric
Mapping (SPM8) software (Wellcome Department of Imaging
Neuroscience, London, UK) and MATLAB R©: adjustment of
acquisition timing across slices, correction for head motion,
spatial normalization using the EPI-MNI template, and
smoothing using a Gaussian kernel with a full width at half-
maximum of 8mm. The normalization step yielded BOLD
images at 3× 3× 3mm voxels.
All subjects who participated in this study also participated in
the aforementioned additional intervention studies, and the MRI
scans not reported in the present study were performed together
with those described herein. Other scans included diffusion-
weighted imaging, resting state fMRI, high-resolution T1-
weighted structural imaging, and another fMRI task (N-back).
fMRI Analyses
A conventional two-level approach using SPM8 was adopted
for event-related fMRI data (Friston et al., 1998). A voxel-
by-voxel multiple regression analysis was conducted for the
first-level within-subject (fixed effects) model. Expected signal
changes were modeled using rectangular waveforms, convolved
with the default SPM hemodynamic response functions for the
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three conditions (Look Neutral, Look Negative, and Decrease
Negative). Low-frequency BOLD signal noise was removed by
high-pass filtering (128 s cut-off).
To evaluate our hypotheses, we first conducted statistical
analyses pertaining to the emotional reactivity contrast (Look
Negative-Look Neutral) associated with the parameter estimates
of the second-level between-subject (random effects)model using
one-sample t-tests. The statistical threshold was set to p < 0.001
for height and corrected to p < 0.05 for multiple comparisons
(false discovery rate) using cluster size and assuming the whole
brain as the search volume (Genovese et al., 2002). We defined
the functional regions of interest (ROIs) within brain regions that
encompassed voxels above our significance threshold during the
emotional reactivity task (Labuschagne et al., 2010). Using these
functional ROIs, we evaluated our primary hypothesis regarding
the relationship between individual differences in OT and AVP
levels and brain activity associated with emotional reactivity.
MarsBaR was used to extract the average parameter estimates
within each functional ROI regarding contrasts in emotional
reactivity on an individual basis.
Next, multiple regression analyses were performed to test
the relationships between neuropeptide (OT and AVP) levels
and brain activation during the processing of negative emotions,
with brain activation used as a predictor. In our first regression
analysis, using OT (or AVP), age, and sex as explanatory
variables, we analyzed the relationship between OT (or AVP) and
brain activation. In our second regression analysis, using the OT-
by-sex (or AVP-by-sex) interaction term, OT (or AVP), age, and
sex (coded men = 1, women = −1) as explanatory variables,
we analyzed the relationship between OT-by-sex (or AVP-by-sex)
and brain activation. OT, AVP, sex, and their interaction terms
were centered in the second analyses to avoid multicollinearity.
Also, menstrual cycle stages were categorically coded and entered
into multiple regression analyses for no-interests of explanatory
variables (menstrual phase = 0; luteal phase = 1; follicular
phase = 2). In the third analysis, using trait anxiety and trait
anxiety-sex interaction, age, and sex, as explanatory variables, we
analyzed the relationship between trait anxiety, trait anxiety-sex
interaction, and brain activation. Trait anxiety and interaction
terms were also centered.
The analyses were performed using SPSS (version 22). All tests
were two-tailed with a threshold of p < 0.05.
RESULTS
Subjective Emotional Reports of Negative
Emotion
Analyses of emotional reports from emotional reactivity trials
revealed that negative images evoked stronger negative affect
than did neutral images, according to self-reported scores on an
8-point scale (mean ± standard error [SE], 6.429 ± 0.698 vs.
1.567± 0.896, respectively; paired t = 22.063, p < 0.001).
Trait OT, Self-Reports of Negative Emotion,
and Sex Differences
OT did not contribute uniquely to amygdala activation during
emotional reactivity trials (β = −0.117, t = −0.760, p = 0.451).
However, the interaction term between OT and sex exhibited
a significant independent effect, indicating that OT levels
negatively correlated with self-report of negative emotion only
in women [β = 0.371, R2 Change = 0.094, F Change (50) =
5.579, p = 0.022]. However, OT did not contribute to self-
reported negative emotion in women after controlling for the
stage in the menstrual cycle (β = −0.418, t = −2.039, p =
0.056).
Trait AVP, Self-Reports of Negative
Emotion, and Sex Differences
No significant association was observed between AVP and
subjective reports of negative emotion (β = 0.110, t = 0.775,
p = 0.442) Furthermore, there was no significant association
between AVP-by-sex interaction and subjective emotional
reports (β = 0.125, t = 0.890, p = 0.378). AVP did not
contribute to negative emotion in women (β = −0.091, t =
−0.413, p = 0.684) once the stage in the menstrual cycle was
controlled for.
Emotional Reactivity-Related Activation
The emotional reactivity trial results (Look Negative-Look
Neutral) are shown as Supplementary Data in Table S1 and Figure
S1. We observed increased activation in the amygdala (Figure 1),
the medial frontal gyrus, the inferior frontal gyrus, and in other
regions. We further defined these regions as functional ROIs
to analyze the relationship between OT (or AVP) and brain
responses to emotional reactivity. The values for Cohen’s d and
effect size related to amygdala activation were 0.888 and 0.406,
respectively.
The Relationship between Trait OT and
Amygdala Activation during the Processing
of Negative Emotion
Neither OT nor the OT-by-sex interaction significantly affected
the amygdala (β = −0.257, t = −1.584, p = 0.129; β =
0.234, t = 1.384, p = 0.173, respectively) or other brain regions.
After correction for stage in the menstrual cycle, OT did not
show significant effects on amygdala activation in women (β
= −0.587, t = −0.347, p = 0.132).
The Relationship between Trait AVP and
Amygdala Activation during the Processing
of Negative Emotion
AVP did not significantly affect activation in the amygdala
(β = 0.029, t = 0.199, p = 0.843) or in other brain
regions during the emotional reactivity trials. However, the
AVP-by-sex interaction significantly affected the amygdala [β
= 0.293, R2 Change = 0.080, F Change (50) = 4.232, p =
0.045], but not other regions, indicating that trait plasma
AVP may play a substantial role in emotional processing in
men, but not women (Figure 2). After correction for stage in
the menstrual cycle, AVP did not show significant effects on
amygdala activation in women (β = −0.128, t = −0.562, p =
0.581).
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FIGURE 1 | The amygdala region (MNI coordinates: −27, −4, −20)
during emotion generation (Look Negative - Look Neutral), with the
statistical threshold set to p < 0.001 for height, corrected to p < 0.05
for multiple comparisons according to cluster size and assuming the
whole brain as a search volume. In this figure, activation is presented at a
threshold of p = 0.05 for illustration purposes only. Activation is shown on an
SPM8 canonical T1 image.
FIGURE 2 | A significant positive correlation is observed between the
log-transformed plasma AVP values and amygdala activity during
emotion generation (Look Negative–Look Neutral) in men, but not in
women. For illustration purposes, scatter plots are unadjusted for any
covariates.
The Relationship between Trait Anxiety and
Amygdala Activation during the Processing
of Negative Emotion
Neither trait anxiety nor trait anxiety-by-sex interaction
significantly affected the amygdala (β = −0.161, t = −0.948,
p = 0.348; β = 0.062, t = 0.386, p = 0.701, respectively) or
other brain regions. After correction for stage in the menstrual
cycle, trait anxiety did not show significant effects on amygdala
activation in women (β = −0.206, t = −0.914, p = 0.372).
DISCUSSION
The present study investigated the neural mechanisms of the
anxiolytic effects of OT and the anxiogenic effects of AVP in
plasma as well as the sex-based modulation of such effects,
focusing on the amygdala. Although a growing body of research
has provided empirical support for the anxiolytic effects of OT
and the anxiogenic effects of AVP in plasma (Londen et al., 1997;
De Kloet et al., 2008; Taylor et al., 2010; Grewen and Light, 2011;
Carson et al., 2014), the neural mechanisms underlying these
effects in humans have not yet been investigated. The present
study provides the first clear evidence that plasma AVP levels
are associated with anxiogenic effects (i.e., increased amygdala
activation during the processing of negative stimuli) in men,
but not in women. Importantly, our findings indicate that sex
modulates the anxiogenic effects of AVP, which is consistent
with previous behavioral studies (Taylor et al., 2010; Brunnlieb
et al., 2013; Lee et al., 2013). These results suggest that the
neural mechanisms underlying the anxiogenic effects of AVP
involve the amygdala, and indicate that AVP may serve as a
valid biological marker for the clinical assessment of individual
differences pertaining to anxiogenic effects in men.
Strong effects of AVP on amygdala functioning may lead to
higher baseline levels of plasma AVP in men relative to women;
this asymmetry may be responsible for the fact that significant
effects of plasma AVP on amygdala activation are found only
in men (Neumann and Landgraf, 2012), although the sex-
based difference remains unresolved due to conflicting evidence
and an unclear mechanism (Meyer-Lindenberg et al., 2011).
AVP neurons project to the amygdala, where AVP receptors
are locally expressed at higher levels in males than they are
in females (Bamshad et al., 1993; Wang and Vries, 1995). In
addition, AVP release within the amygdala has been observed in
response to stressful emotional experiences in male rats (Ebner
et al., 1999; Bosch and Neumann, 2010), and this release is
greater in animals with stronger anxiety behaviors (Bosch and
Neumann, 2010). The amygdala also projects to other brain
regions, such as the paraventricular nucleus, the bed nucleus
of the stria terminalis, and the hypothalamus, all of which
exhibit elevated AVP mRNA expression levels (Ma et al., 1997;
Wotjak et al., 2001) and are considered to be, along with the
amygdala, critically involved in peripheral and central AVP
communication. Among these regions, the magnocellular AVP
neurons of the paraventricular nucleus communicate with the
limbic region, including the amygdala, and ultimately project to
the posterior pituitary (Neumann and Landgraf, 2012). This body
of evidence pertaining to systemic AVP circulation provides a
partial explanation of the mechanism underlying the synergistic
nature of peripheral and central AVP processing in men.
We observed male-specific anxiogenic effects of AVP, which
are consistent with proposed synergistic mechanisms involving
testosterone and AVP in male subjects in animal studies,
as described below. The amplifying effects of male gonadal
hormones on the influence of AVP on amygdala functioning
may result in stronger brain-peripheral AVP communication
in men than in women. AVP expression in the amygdala
is known to be greatly influenced by gonadal steroids. In
rats, testosterone directly acts on AVP-containing cells in the
amygdala (de Vries, 2008), and after receiving injections of
testosterone, male rats have greater numbers of AVP mRNA-
containing cells in the amygdala than do female rats (Urban
et al., 1991; De Vries et al., 1994). Testosterone also influences
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AVP levels in brain regions such as the bed nucleus of the
stria terminalis and the hypothalamus, where AVP projections
are prominent, and coordinated reactions between these regions
and the amygdala have been detected after affective experiences
(Albers, 2012). Importantly, testosterone administration has been
shown to strengthen AVP fiber networks in the amygdala in
male rats (De Vries and Al-Shamma, 1990). Moreover, previous
neuroimaging studies have suggested that in men, higher levels of
testosterone predicted elevated activation in the amygdala during
the processing of threatening stimuli (Manuck et al., 2010).
Together with these previous findings regarding the effects of
testosterone on AVP in the amygdala, our results would indicate
that the observed relationship between peripheral AVP levels
and amygdala activation in men may be partly influenced by the
effects of testosterone on AVP functioning.
In the present study, endogenous AVP had no effect on the
subjective experiences reported by participants while processing
negative stimuli. Assessments based on brain measurements
(e.g., BOLD signals) may differ among self-reports and
peripheral biomarkers. For example, a previous study observed a
relationship between brain activation and peripheral biomarkers
in the absence of significant associations between self-reports
of emotions and peripheral biomarkers (Gross and Levenson,
1993). In addition, intranasal AVP administration was shown to
increase amygdala-medial prefrontal cortex activation during the
processing of negative stimuli without exerting a significant effect
on subjective reports of emotion (Zink et al., 2010). Together
with the results of previous studies, our current findings indicate
that brain measurements of emotional responses are often more
accurately reflective of measured plasma AVP levels than are
subjects’ emotional self-reports.
Some limitations of the study are worth mentioning in light
of our interpretation of the results. First, the sample size was
relatively small. Although our sample size represents a relatively
large fMRI study, previous studies of plasma neuropeptides
have used larger samples (N = 473) (Weisman et al., 2013).
Second, although our data demonstrated a correlation between
amygdala activity and peripheral AVP levels in men, we cannot
be sure that the portion of the amygdala we investigated in
our study included the region with the highest concentration of
OT and AVP receptors. Third, we used increases and decreases
in amygdala activation as indices of anxiogenic and anxiolytic
effects, respectively. Although our subtraction analysis (aversive
pictures minus neutral pictures) yielded robust evidence of
activation in the amygdala, resulting in significantly higher levels
of activation during the viewing of aversive images relative to
neutral ones, we did not find a relationship between subjective
reports of chronic negative affect (i.e., trait anxiety) and amygdala
activation. This may be because our subjects generally came
from a healthy population and did not have particularly high
levels of anxiety (mean ± SE, 45.796 ± 8.677 for whole sample;
43.16 ± 6.459 for male, 48.542 ± 9.908 for female). Hence,
AVP values may be a more sensitive indicator of amygdala
activation than chronic negative affect in healthy populations.
For example, a previous study failed to show changes in anxiety
scores in healthy men following administration of AVP, but did
report increased amygdala-medial prefrontal cortex connectivity
in these participants during negative emotional processing (Zink
et al., 2010). Future studies are needed to address these issues,
including studies that recruit clinical patients or individuals with
higher anxiety scores. Fourth, although stage in the menstrual
cycle was assessed at the time of blood sampling and was
controlled for in our analyses, we did not obtain information
pertaining to the menstrual cycle on the day of the MRI, which
may have partially distorted the results obtained from our female
participants. Fifth, there is considerable controversy regarding
the relationship between peripheral levels of these neuropeptides
and their central availability. A crucial issue is whether plasma
levels of these hormones reflect these brain functions (Meyer-
Lindenberg et al., 2011). The relation between central and
plasma oxytocin is not completely understood. A further animal
study on this issue would be of value to the field. Sixth, the
present paper reports mean OT levels that are double the
upper threshold of the expected range between 1 and 10 pg/mL
(McCullough et al., 2013). We performed extraction procedures
prior to conducting the OT assay following the paper’s suggestion
(McCullough et al., 2013). Even so, the measurements might
contain multiple immunoreactive products that are erroneously
tagged as OT (McCullough et al., 2013). Some of these non-
OT immunoreactive molecules may unexpectedly amplify mean
OT levels, which may lead to non-significant results of the
relationships between OT and the amygdala activation. Finally,
we did not measure plasma OT and AVP on the day of the MRI
and we cannot perfectly guarantee the stability of OT and AVP
between the time of blood sampling andMRI scanning, leading to
some uncertainty about the levels of these neuropeptides on the
day of MRI testing; however, our assay supports the day-to-day
stability of plasma samples.
To our knowledge, this is the first study to investigate the
underlying neural signatures of the anxiolytic effects of OT and
the anxiogenic effects of AVP using plasma, and to investigate
sex-based modulations of these effects. Our findings showed
anxiogenic effects of plasma AVP as reflected in the amygdala
activity of men, but not of women. This may reflect more robust
peripheral and central AVP communication in men relative
to women, possibly influenced by the effects of testosterone
on AVP functioning. Our results indicate the potential validity
and usefulness of AVP plasma level as an index of individual
differences pertaining to anxiogenic effects and as a clinically
relevant marker.
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